Introduction

Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab, and toward more precisely engineering the donor graft itself to separate the beneficial, disease-fighting parts of a transplant from the harmful, graft-versus-host parts. This year brought early data on both fronts, plus the first FDA approval built on the latter idea, and a maintenance strategy borrowed from newly available AML drugs.

Making CAR T-Cells Inside the Body, Without a Lab

Manufacturing CAR T-cells traditionally requires collecting a patient's T-cells, sending them to a lab for genetic engineering, and infusing the modified product back, a process that takes weeks and typically requires bridging therapy and lymphodepleting chemotherapy in the interim. A first-in-human study from Australia tested a fundamentally different approach: a modified, replication-competent lentivirus engineered to enter only CD3-positive T-lymphocytes, where it delivers a fully humanized BCMA-directed CAR construct directly, generating CAR T-cells inside the patient's own body.

This phase 1, dose-escalation study enrolled patients with relapsed or refractory multiple myeloma after three or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Across the first infusions in up to 18 patients (median age 67, most with triple-refractory disease and prior autologous transplant), all evaluable patients achieved MRD-negativity in the bone marrow within one month. Among the six patients with at least four months of follow-up, four achieved a stringent complete response and two a very good partial response, all MRD-negative.

Safety was notably favorable for a T-cell-based therapy: no grade 3 or higher cytokine release syndrome, only one case of grade 3 neurotoxicity (successfully managed with supportive care), and no delayed neurotoxicity of the kind sometimes seen with standard BCMA-directed CAR T-cell products. Critically, this cohort received no lymphodepleting chemotherapy at all. If this approach holds up in larger studies, it could represent a paradigm shift, overcoming some of the biggest bottlenecks in current CAR T-cell access: manufacturing wait times, insurance authorization delays, and the need for bridging therapy.

Another distinct (Ex-vivo) BCMA-directed CAR T-cell candidate was tested in a multi-site single arm open-label phase 1/2 trial for anti-CD38-exposed relapsed myeloma. The trial enrolled 23 patients (20 infused) and reported a 95 percent hematologic complete response rate after single infusion, with very low-grade cytokine release syndrome and no neurotoxicity, though organ-level response data (important for confirming the depth of benefit beyond a hematologic marker) were not yet mature at the time of presentation.

(A note on sourcing: the specific commercial or program names for both in vivo and standard-manufacture CAR T-cell candidates described here could not be independently confirmed against the primary abstracts and should be verified before these sections are finalized.)

Tregzi (Orca-T): The First FDA-Approved Regulatory T-Cell Therapy

For decades, allogeneic transplant has struggled to balance graft-versus-host disease against the complications of excessive immune suppression, particularly relapse and infection. A precision-engineered graft, marketed as Tregzi (development name Orca-T), separates a donor's stem cells, regulatory T-cells, and conventional T-cells into distinct components, infusing the stem cells and regulatory T-cells first, then the conventional T-cell population two days later. The regulatory T-cells expand early, calm tissue inflammation at the site of active chemotherapy-related injury, and establish tolerance before the graft-versus-leukemia-active conventional T-cells arrive.

The FDA approval, granted June 30, 2026, rests on the phase 3 PRECISION-T trial, which randomized 187 patients with acute leukemia in remission or MDS with <10% bone marrow blasts undergoing myeloablative conditioning to either the conventional unmanipulated stem cell graft with tacrolimus/mycophenolate prophylaxis, or the split-dose Tregzi approach with a shorter course of tacrolimus. The trial met its primarmy endpoint, with 1-year moderate-to-severe chronic GVHD-free survival nearly doubled, from 38.4 percent with standard of care to 78 percent with Tregzi. Non-relapse mortality, despite all patients receiving myeloablative conditioning, was strikingly low at 3.4 percent versus 13 percent with standard of care. Health-related quality of life (HRQOL) outcomes were presented later this year, which showed that patients who received Tregzi had a faster recovery of HRQOL- returning to baseline around three months versus roughly a year with standard tacrolimus-based prophylaxis.

Maintenance Menin Inhibition After Transplant for High-Risk AML

To date, no maintenance therapy was approved after allogeneic transplant for NPM1-mutated, KMT2A-rearranged, or NUP98-rearranged AML, historically adverse-risk subtypes with high relapse rates even after transplant. Now that menin inhibitors have shown activity in relapsed disease with these alterations, a pooled analysis from three induction trials examined outcomes in 24 patients (split between adults and children) who proceeded to transplant and received menin inhibitor maintenance afterward. Most patients were in second or later remission at transplant, a genuinely high-risk group; over half were undergoing their second transplant attempt.

Maintenance started a median of about three months post-transplant and continued for a median of ten months, with many patients completing the full three years intended. The main toxicity was grade 3 thrombocytopenia, generally manageable with dose adjustment, and no increased signal for graft-versus-host disease or infection. One-year and two-year overall survival were both around 90 percent, and 2-year event-free survival was 72 percent, figures that compare favorably to the roughly 40 to 50 percent two-year survival historically expected in this high-risk population. Cumulative relapse incidence was similarly reduced compared with historical controls (15 percent versus roughly 40 percent at one year in patients transplanted in second remission or beyond).

This is a small, retrospective, pooled dataset without a randomized comparison, but it is a genuinely promising option in a disease area where randomized trials are difficult to run and post-transplant relapse has long been the dominant cause of treatment failure.

For Patients

Two changes are worth understanding if you or a family member is facing a stem cell transplant or CAR T-cell therapy for a blood cancer. First, a new, more precisely engineered version of a stem cell transplant, now FDA-approved and marketed as Tregzi, can meaningfully lower the risk of a serious, long-lasting transplant complication called chronic graft-versus-host disease, without increasing the risk of the cancer coming back. Second, for the specific, higher-risk genetic subtypes of AML that have no approved maintenance option after transplant, a menin inhibitor pill taken after transplant is showing real promise at keeping the leukemia from returning. Both approaches are relatively new; patients should ask their transplant team directly whether either applies to their specific situation.

Key Takeaways

  • An investigational in vivo CAR T-cell approach, using a modified lentivirus to generate BCMA-directed CAR T-cells directly inside the body, produced MRD-negative responses in all evaluable relapsed myeloma patients without any lymphodepleting chemotherapy, an early but potentially access-transforming result.

  • Tregzi (Orca-T), the first FDA-approved regulatory T-cell-based transplant therapy, nearly doubled 1-year chronic GVHD-free survival and substantially lowered non-relapse mortality compared with standard transplant, based on the phase 3 PRECISION-T trial.

  • Quality of life recovered roughly four times faster with Tregzi than with standard tacrolimus-based GVHD prophylaxis.

  • Menin inhibitor maintenance after allogeneic transplant shows encouraging early survival and relapse data in NPM1-mutated, KMT2A-rearranged, and NUP98-rearranged AML, a historically high-relapse population with no previously approved maintenance option.

  • Both the in vivo CAR T-cell approach and the pooled menin inhibitor maintenance data remain early and require larger, ideally randomized confirmation before they change standard practice broadly.

References

  1. Orca Bio. TREGZI (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) prescribing information and PRECISION-T trial data. FDA approval June 30, 2026.

  2. Pooled analysis of menin inhibitor maintenance therapy after allogeneic transplant for NPM1-mutated, KMT2A-rearranged, or NUP98-rearranged AML. Presented ASCO/ASH 2025-2026.

  3. First-in-human study of an in vivo, lentivirus-delivered BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma. Presented ASH 2025.